You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
明德生物(002932.SZ)一季度預盈13.5億-14.5億元 同比增長295.61%-324.91%
格隆匯 04-13 20:31

格隆匯4月13日丨明德生物(002932.SZ)公佈,預計2022年第一季度歸屬於上市公司股東的淨利潤13.5億元-14.5億元,同比增長295.61%-324.91%;歸屬於上市公司股東的扣除非經常性損益後的淨利潤13.5億元-14.5億元,同比增長296.68%-326.06%。

業績變動原因如下:120221月以來,國內多地奧密克戎疫情爆發國內新增病例創新高,各地為防控疫情加大了新冠核酸檢測頻率,增加了對新冠核酸檢測試劑的需求,公司憑藉靈敏度高、操作便捷的產品和優質的客户服務,新冠核酸檢測試劑市佔率持續走高,新冠核酸檢測試劑及服務等相關收入大幅增長。

2、2022年3月國務院應對新冠疫情聯防聯控機制綜合組決定在核酸檢測基礎上,增加抗原檢測作為補充。公司2022年3月15日國內新獲批新冠抗原檢測試劑盒並陸續在全國多個省份中標,上海、吉林、山東等多地疫情反覆新增了對公司新冠抗原檢測試劑盒的需求,並帶來相關產品經營業績的增加。

3、2022年1月以來海外奧密克戎新冠疫情不斷反覆,市場對新冠抗原檢測試劑盒需求增加,公司新冠抗原檢測試劑盒出口訂單同比大幅增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account